Meningococcal B

ApprovedBiologic

GSK

Meningococcal B is one of 54 biologic programs targeting Rheumatic Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseActive, not recruiting

Rheumatic DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Rheumatic Disease

#DrugCompanyPhaseTrials

Anjeso

Boehringer Ingelheim

Approved

1 2

Oruvail

WWyeth-Lederle Vaccines

COVID-19 Vaccine

2 4

Jascayd

Ilaris

1 6

Orencia

Bristol-Myers Squibb

Phase 2

1 7

Cosentyx

Novartis

Phase 2

1 8

Taltz

Eli Lilly

Phase 2

1 9

Bimzelx

UCB

Phase 2

1 10

Stelara

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalNot yet recruiting

Rheumatic Disease

NCT07252804

Clinical

Trials by Indication[1]

Satisfaction1 trial

Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction

Completed·CCanadian Immunization Research Network·Phase 4·NCT02868970·2,404 enrolled

Rheumatic Disease1 trial

Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases

Not yet recruiting·UUniversity of Sao Paulo General Hospital·Phase 4·NCT07252804·263 enrolled

Adolescent1 trial

Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine

Completed· GSK logo

GSK·Phase 2·NCT00356369·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Meningococcal B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meningococcal B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meningococcal B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: GSK

Meningococcal B

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Satisfaction1 trial

Rheumatic Disease1 trial

Adolescent1 trial

References

Drug Info

Quick Facts

Related News